In the ever-evolving landscape of cancer research and treatment,the quest for novel and non-invasive imaging techniques has become crucial for accurate diagnosis and effective therapy.This study[1]successfully develop...In the ever-evolving landscape of cancer research and treatment,the quest for novel and non-invasive imaging techniques has become crucial for accurate diagnosis and effective therapy.This study[1]successfully developed a good manufacturing practices(GMP)grade ^(89)Zr-labeled anti-Claudin18.2(CLDN18.2)recombinant humanized antibody TST001.^(89)Zr-DFO-TST001 exhibited high radiochemical purity(>99%)and specific activity(24.15±1.34 GBq/mmol).It demonstrated good specificity and rapid tumor accumulation in vivo and in vivo.Through immuno-PET imaging,it enables non-invasive visualization and quantification of CLDN18.2 expression level in CLDN18.2-positive gastrointestinal tumor models.展开更多
Claudin-18.2(CLDN18.2)is a tight junction protein that is typically expressed only in normal gastric mucosal cells.When malignancy occurs,cell polarity is lost,intercellular adhesion structures are destroyed,and CLDN1...Claudin-18.2(CLDN18.2)is a tight junction protein that is typically expressed only in normal gastric mucosal cells.When malignancy occurs,cell polarity is lost,intercellular adhesion structures are destroyed,and CLDN18.2 is therefore exposed to the surface of tumor cells[1].CLDN18.2 is specifically expressed in approximately 40%of human epidermal growth factor receptor 2(HER2)-negative gastrointestinal cancers,making it a promising emerging therapeutic target.As recently reported,zolbetuximab,an CLDN18.2 targeting antibody,has shown amazing efficacy in patients with CLDN18.2-positive and HER2-negative gastric cancers[2].In clinical practice,the assessment of CLDN18.2 expression status is crucial to the determination of treatment regimen for patients.Molecular imaging can be used as a non-invasive test for diagnosis,staging,and efficacy monitoring.The results of molecular imaging of CLDN18.2 have been published continuously,and the development of CLDN18.2 molecular probe is of great significance for the development of tumor targeted therapy(Fig.1).展开更多
基金supported by the National University of Singapore(Grant Nos.:NUHSRO/2021/097/Startup/13,NUHSRO/2020/133/Startup/08,NUHSRO/2023/008/NUSMed/TCE/LOA,NUHSRO/2021/034/TRP/09/Nanomedicine,and NUHSRO/2021/044/Kickstart/09/LOA)National Medical Research Council(Grant Nos.:OFYIRG23jan-0025,OFYIRG23jan-0017,MOH-001254-01,and CG21APR1005)+2 种基金Singapore Ministry of Education Academic Research Fund(Grant Nos.:NUHSRO/2022/093/T1/Seed-Sep/06 and MOE-000387-01)National Research Foundation(Grant No.:CRP28-2022RS-0001),National Natural Science Foundation of China(Grant No.:82202206)Beijing Natural Science Foundation(Grant No.:7224365).
文摘In the ever-evolving landscape of cancer research and treatment,the quest for novel and non-invasive imaging techniques has become crucial for accurate diagnosis and effective therapy.This study[1]successfully developed a good manufacturing practices(GMP)grade ^(89)Zr-labeled anti-Claudin18.2(CLDN18.2)recombinant humanized antibody TST001.^(89)Zr-DFO-TST001 exhibited high radiochemical purity(>99%)and specific activity(24.15±1.34 GBq/mmol).It demonstrated good specificity and rapid tumor accumulation in vivo and in vivo.Through immuno-PET imaging,it enables non-invasive visualization and quantification of CLDN18.2 expression level in CLDN18.2-positive gastrointestinal tumor models.
文摘Claudin-18.2(CLDN18.2)is a tight junction protein that is typically expressed only in normal gastric mucosal cells.When malignancy occurs,cell polarity is lost,intercellular adhesion structures are destroyed,and CLDN18.2 is therefore exposed to the surface of tumor cells[1].CLDN18.2 is specifically expressed in approximately 40%of human epidermal growth factor receptor 2(HER2)-negative gastrointestinal cancers,making it a promising emerging therapeutic target.As recently reported,zolbetuximab,an CLDN18.2 targeting antibody,has shown amazing efficacy in patients with CLDN18.2-positive and HER2-negative gastric cancers[2].In clinical practice,the assessment of CLDN18.2 expression status is crucial to the determination of treatment regimen for patients.Molecular imaging can be used as a non-invasive test for diagnosis,staging,and efficacy monitoring.The results of molecular imaging of CLDN18.2 have been published continuously,and the development of CLDN18.2 molecular probe is of great significance for the development of tumor targeted therapy(Fig.1).
